Fairmount Funds Management Ups Stake in Viridian Therapeutics

TL;DR

Fairmount Funds now owns 5.1% of Viridian Therapeutics after filing an amendment.

AI Summary

Fairmount Funds Management LLC, through Fairmount Healthcare Fund II GP LLC, has amended its Schedule 13D filing regarding Viridian Therapeutics, Inc. As of September 17, 2024, Fairmount Funds Management LLC holds 1,640,000 shares of Viridian Therapeutics common stock, representing 5.1% of the outstanding shares. This filing indicates a change in their beneficial ownership.

Why It Matters

This filing signals a potential shift in significant shareholder influence or strategy for Viridian Therapeutics, which could impact its stock price and future corporate actions.

Risk Assessment

Risk Level: medium — Changes in significant beneficial ownership can indicate evolving investor sentiment or strategic intentions, potentially leading to price volatility.

Key Numbers

• 1,640,000 — Shares Held (Fairmount Funds Management LLC's beneficial ownership in Viridian Therapeutics.)
• 5.1% — Ownership Stake (Represents the percentage of Viridian Therapeutics' outstanding common stock held by Fairmount Funds Management LLC.)

Key Players & Entities

• Fairmount Funds Management LLC (company) — Filing entity
• Fairmount Healthcare Fund II GP LLC (company) — Related entity holding shares
• Viridian Therapeutics, Inc. (company) — Subject company
• 1,640,000 (dollar_amount) — Number of shares held
• 5.1% (dollar_amount) — Percentage of shares held
• 20240917 (date) — Filing date

FAQ

Key Financial Figures

• $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti
• $30,000,000.00 — tock of the Company for an aggregate of $30,000,000.00 in an underwritten public offering (the

Filing Documents

• tm2424267d1_sc13da.htm (SC 13D/A) — 71KB
• 0001104659-24-100768.txt ( ) — 73KB

of the Statement is hereby amended and supplemented as follows

Item 3 of the Statement is hereby amended and supplemented as follows: In aggregate, the Reporting Persons have voting and dispositive power over 15,556,685 shares of Common Stock of the Company, which is comprised of (a) 3,445,813 shares of Common Stock, and (b) 12,110,872.18 (rounded to 12,110,872 shares for purposes of reporting in this Schedule 13D) shares of Common Stock issuable upon conversion of 133,191 shares of Series A Preferred Stock and 48,463 shares of Series B Preferred Stock, the conversion of which is subject to a beneficial ownership limitation of 19.99% of the outstanding Common Stock. On September 13, 2024, Fund II purchased a total of 1,600,000 shares of Common Stock of the Company for an aggregate of $30,000,000.00 in an underwritten public offering (the “ Offering ”). The shares were purchased with working capital. Fairmount and Fairmount GP II do not own any shares of Common Stock, Series A Preferred Stock or Series B Preferred Stock directly. Fairmount and Fairmount GP II are deemed to beneficially own the shares Common Stock, Series A Preferred Stock and Series B Preferred Stock held by Fund II. Fairmount and Fairmount GP II disclaim beneficial ownership of such shares of Common Stock, Series A Preferred Stock and Series B Preferred Stock except to the extent of their pecuniary interest therein. Item 4. Purpose of Transaction

is hereby amended and supplemented as follows

Item 4 is hereby amended and supplemented as follows: Fund II purchased the shares of Common Stock referenced in Item 3 for investment purposes. Lock-up Agreement Pursuant to lock-up agreements signed in connection with the Offering, the Reporting Persons and each director and officer of the Company agreed with the representatives of the underwriters, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Exchange Act) or any other securities so owned that are convertible into or exercisable or exchangeable for Common Stock; or dispose of any shares of Common Stock, options to acquire shares of Common Stock, or securities exchangeable or exercisable for or convertible into shares of Common Stock currently or hereafter owned either of record or beneficially. This restriction terminates after the close of trading of the Common Stock on and including the 60th day after the date of the prospectus supplement relating to the Offering. Item 5. Interest in Securities of the Company The percentages used in this Schedule 13D are calculated based upon 74,556,520 shares of Common Stock outstanding, consisting of 63,889,920 shares of Common Stock outstanding as of August 5, 2024 plus 10,666,600 shares of Common Stock sold in the Offering. The Reporting Persons’ securities include (a) 3,445,813 shares of Common Stock and (b) 12,110,872.18 (rounded to 12,110,872 shares for purposes of reporting in this Schedule 13D) shares of Common Stock issuable upon conversion of 133,191 shares of Series A Preferred Stock and 48,463 shares of Series B Preferred Stock, the conversion of which is subject to a beneficial ownership limitation of 19.99% of the outstanding Common Stoc

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement as of September 17, 2024. FAIRMOUNT FUNDS MANAGEMENT LLC By: /s/ Peter Harwin /s/ Tomas Kiselak Peter Harwin Tomas Kiselak Managing Member Managing Member FAIRMOUNT HEALTHCARE FUND II GP LLC By: /s/ Peter Harwin /s/ Tomas Kiselak Peter Harwin Tomas Kiselak Managing Member Managing Member

View Full Filing

View this SC 13D/A filing on SEC EDGAR